[go: up one dir, main page]

ES2013129A6 - Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina. - Google Patents

Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.

Info

Publication number
ES2013129A6
ES2013129A6 ES8901101A ES8901101A ES2013129A6 ES 2013129 A6 ES2013129 A6 ES 2013129A6 ES 8901101 A ES8901101 A ES 8901101A ES 8901101 A ES8901101 A ES 8901101A ES 2013129 A6 ES2013129 A6 ES 2013129A6
Authority
ES
Spain
Prior art keywords
propinylamine
propil
methyl
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8901101A
Other languages
English (en)
Inventor
Manfred Karobath
Jorg Reinhardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somerset Pharmaceuticals Inc
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10634325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2013129(A6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of ES2013129A6 publication Critical patent/ES2013129A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROCEDIMIENTO DE OBTENCION DE UNA COMPOSICION FARMACEUTICA A BASE DE N-METIL-N-(1-FENIL-2-PROPIL)-2-PROPINILAMINA. COMPRENDE DISPERSAR LA SUSTANCIA ACTIVA N-METIL-N-(1-FENIL-2-PROPIL)-2-PROPINILAMINA, EN FORMA RACEMICA U OPTIMAMENTE ACTIVA O EN FORMA DE SUS SALES DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLES, EN UN GEL O POLIMERO SOLIDO, TAL COMO UN POLIMERO HIDROFILO. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON.
ES8901101A 1988-03-29 1989-03-29 Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina. Expired - Lifetime ES2013129A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888807504A GB8807504D0 (en) 1988-03-29 1988-03-29 Improvements in/relating to organic compounds

Publications (1)

Publication Number Publication Date
ES2013129A6 true ES2013129A6 (es) 1990-04-16

Family

ID=10634325

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8901101A Expired - Lifetime ES2013129A6 (es) 1988-03-29 1989-03-29 Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.

Country Status (18)

Country Link
EP (1) EP0404807B1 (es)
JP (1) JP2533211B2 (es)
KR (1) KR0136870B1 (es)
AU (1) AU630088B2 (es)
CA (1) CA1336071C (es)
DE (1) DE68907406T2 (es)
ES (1) ES2013129A6 (es)
FI (1) FI895681A7 (es)
GB (1) GB8807504D0 (es)
GR (1) GR1003711B (es)
HU (1) HU207441B (es)
IE (1) IE62955B1 (es)
IL (1) IL89748A (es)
MY (1) MY105121A (es)
NZ (1) NZ228467A (es)
PT (1) PT90120B (es)
WO (1) WO1989009051A1 (es)
ZA (1) ZA892321B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
EP0593807A1 (en) * 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
ATE205706T1 (de) * 1993-04-20 2001-10-15 Hexal Ag Wirkstoffpflaster
JP3839049B2 (ja) * 1994-06-03 2006-11-01 テムド トラスト メタ位置換のアリルアルキルアミン類ならびに治療および診断のためのその使用
HU223475B1 (hu) * 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6033682A (en) * 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
JPH11506744A (ja) 1995-06-07 1999-06-15 ノウブン ファーマシューティカルズ インク． 室温で液体である低分子量薬を含む経皮組成物
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DE19533089C1 (de) 1995-09-07 1997-05-22 Hexal Ag Tacrin-Pflaster
DE19533772C1 (de) * 1995-09-12 1998-01-02 Hexal Ag Tacrin/Selegilin-Pflaster
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
ATE222101T1 (de) 1998-03-16 2002-08-15 Somerset Pharmaceuticals Inc Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
DE69916492T3 (de) † 1998-12-07 2008-08-14 J. Dev Ltd., Athlone Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen
AU2002354017B2 (en) 2001-11-05 2007-08-16 Krele Pharmaceuticals, Inc. Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
AU2005309601A1 (en) 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2008264476B2 (en) * 2007-06-21 2013-03-28 Fujimoto Co., Ltd. Composition for transdermal or transmucosal administration
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
JP5843357B2 (ja) 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
EP2440228B8 (en) 2009-06-08 2023-02-22 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
PE20121539A1 (es) 2009-06-08 2012-12-06 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion
JP2013502458A (ja) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
PT3564260T (pt) 2012-02-15 2023-01-18 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
WO2018071656A1 (en) 2016-10-14 2018-04-19 Knowles Enterprises Inc. Formulations for treatment of migraines
JP7748175B2 (ja) 2016-12-02 2025-10-02 バイオベラティブ セラピューティクス インコーポレイテッド キメラ凝固因子を使用して血友病性関節症を処置する方法
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
CN112512555A (zh) 2018-05-18 2021-03-16 比奥维拉迪维治疗股份有限公司 治疗血友病a的方法
IL298815A (en) 2020-06-25 2023-02-01 Amunix Pharmaceuticals Inc Bispecific compositions targeting HER-2 and methods for their preparation and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139127A1 (en) * 1983-08-22 1985-05-02 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Transdermal drug delivery device and its preparation
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin

Also Published As

Publication number Publication date
JP2533211B2 (ja) 1996-09-11
EP0404807A1 (en) 1991-01-02
FI895681A0 (fi) 1989-11-28
MY105121A (en) 1994-08-30
WO1989009051A1 (en) 1989-10-05
GB8807504D0 (en) 1988-05-05
PT90120B (pt) 1994-06-30
HU207441B (en) 1993-04-28
DE68907406D1 (de) 1993-08-05
CA1336071C (en) 1995-06-27
IE890921L (en) 1989-09-29
ZA892321B (en) 1990-12-28
AU630088B2 (en) 1992-10-22
IL89748A (en) 1993-07-08
FI895681A7 (fi) 1989-11-28
AU3290089A (en) 1989-10-16
KR900700089A (ko) 1990-08-11
GR890100190A (el) 1990-01-19
JPH02503677A (ja) 1990-11-01
GR1003711B (el) 2001-10-25
EP0404807B1 (en) 1993-06-30
PT90120A (pt) 1989-11-10
NZ228467A (en) 1991-12-23
DE68907406T2 (de) 1993-10-14
KR0136870B1 (ko) 1998-04-25
HU892559D0 (en) 1990-01-28
HUT55220A (en) 1991-05-28
IE62955B1 (en) 1995-02-20

Similar Documents

Publication Publication Date Title
ES2013129A6 (es) Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.
MA23608A1 (fr) Forme de dosage ii d'unite multiple en comprime
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
CY1107711T1 (el) Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων
SE8800731L (sv) Fenylkarbamat
FR2673538B1 (fr) Composition a base de 3-[2-(dimethylamino)ethyl]-n-methyl-1h-indole-5 methanesulfonamide pour l'administration buccale.
JP2007526794A5 (es)
ES2176234T3 (es) Sistema terapeutico transdermal con galantamina como componente activo.
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
PT85055A (pt) Processo para a preparacao de composicoes farmaceuticas contendo ester metilico da levodopa
ES541513A0 (es) Procedimiento para la obtencion de comprimidos de sustancia activa farmaceutica, de rapida desintegracion
ES2143641T3 (es) Expresion en superficie de una enzima en la terapia genica a base de promedicamentos.
CA2009593A1 (en) Medicament containing dihydrolipoic acid as active substance
DK324687A (da) Transdermalt farmeceutisk praeparat
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
ES2033682T3 (es) Procedimiento para preparar una composicion farmaceutica que contiene acido 2-(2-fluoro-4-bifenilil)propionico o una de sus sales.
ES2029853T3 (es) Un metodo para preparar una base para pomada de gel.
ES2051733T3 (es) Procedimiento de obtencion de un medicamento a base de tamoxifen para uso local.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
ES2111104T3 (es) Utilizacion de nadh y nadph para la fabricacion de un medicamento para el tratamiento de la enfermedad de alzheimer.
NO172043C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater
SE9301877D0 (sv) In situ gel for therapeutic use
ES2043719T3 (es) Administracion de farmacos por via percutanea.
PE8798A1 (es) Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
DK249288A (da) Substituerede silylalkylenaminer og farmaceutisk acceptable salte deraf, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: SOMERSET PHARMACEUTICALS INC.

FD1A Patent lapsed

Effective date: 20090330